Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: tube (380), vessel (100), duct (25)

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This regimen will only b
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Tisacel-Bendamustine(90)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – BENDAMUSTINE (90) Regimen This regimen will only be available to prescribe
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Bendamustine90.pdf

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available t
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available to prescri
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

Laboratory medicine investigations rev 25

Description: University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.7a UHSFT Pathology Laboratory Medicine List of Investigations For information o
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Laboratory-medicine-investigations.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Regimen This regimen is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Elranatamab

Description: Chemotherapy Protocol ELRANATAMAB This protocol may require funding Regimen • Elranatamab Indication • Monotherapy for the treatment of adult patients with relapse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Elranatamab-Ver2.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen will only be available to presc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication • Treatment of adult patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indication • Treatment of adult patients
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

11 to 20 of 24

Previous 1 2 3 Next